Huifeng Bio-Pharmaceutical (HFGB.OB) Reaffirms 2010 Guidance on Solid Q2 Financial Results
Huifeng Bio-Pharmaceutical Technology Inc., a developer and producer of botanical extracts and other raw materials for pharmaceuticals and food additives, today reiterated its financial results for its second quarter ended June 30, 2010. "We are pleased to report record revenue and operating income in the quarter," Jing'an Wang, the company's CEO stated in the press release. "The large increase in profitability and top line growth can be attributed to the increase in our sales of pharmaceutical raw-material and pharmaceutical intermediates. We have seen increased orders of both Rutin series products and Diosmin. We plan on focusing to fulfill the entire…